Eddie Myers

Summary

Country: UK

Publications

  1. ncbi The influence of preclinical anaemia on outcome following total hip replacement
    E Myers
    Regional Orthopaedic Unit, Our Lady s Hospital, Navan, Co Meath, Ireland
    Arch Orthop Trauma Surg 124:699-701. 2004
  2. ncbi Case report of recurrent acute appendicitis in a residual tip
    Donal P O'Leary
    Department of Surgery, Saint Luke s Hospital, Kilkenny, Ireland
    Cases J 3:14. 2010
  3. ncbi CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer
    Dhafir Al-azawi
    Department of Surgery, St, Vincent s University Hospital, Dublin, Ireland
    BMC Cancer 6:220. 2006

Collaborators

  • Donal P O'Leary
  • Dhafir Al-azawi
  • Joe Coyle
  • Ian Wilson
  • Enda W McDermott
  • Niall O Higgins
  • Arnold D K Hill
  • Michael J Duffy
  • Gabrielle Kelly

Detail Information

Publications3

  1. ncbi The influence of preclinical anaemia on outcome following total hip replacement
    E Myers
    Regional Orthopaedic Unit, Our Lady s Hospital, Navan, Co Meath, Ireland
    Arch Orthop Trauma Surg 124:699-701. 2004
    ..The patient population who undergo total hip replacement (THR) are elderly and are more likely to fall into this category. Our aim was to assess the effect of preclinical anaemia on a patient's postoperative course...
  2. ncbi Case report of recurrent acute appendicitis in a residual tip
    Donal P O'Leary
    Department of Surgery, Saint Luke s Hospital, Kilkenny, Ireland
    Cases J 3:14. 2010
    ..Residual appendicitis involving the stump of the appendix has been well described in the literature in the past...
  3. ncbi CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer
    Dhafir Al-azawi
    Department of Surgery, St, Vincent s University Hospital, Dublin, Ireland
    BMC Cancer 6:220. 2006
    ..Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer...